Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.

Neoplasia (New York, N.Y.) - 1 Nov 2008

Chesler Louis, Goldenberg David D, Collins Rodney, Grimmer Matt, Kim Grace E, Tihan Tarik, Nguyen Kim, Yakovenko Slava, Matthay Katherine K, Weiss William A

Abstract excerpt

Chemoresistance in neuroblastoma is a significant issue complicating treatment of this common pediatric solid tumor. MYCN-amplified neuroblastomas are infrequently mutated at p53 and are chemosensitive at diagnosis but acquire p53 mutations and chemoresistance with relapse. Paradoxically, Myc-driven transformation is thought to require apoptotic blockade. We used the TH-MYCN transgenic murine model to examine the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cyclophosphamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p53

Share to N-Myc Proto-Oncogene Protein

Share to Neuroblastoma

Share to Oncogene Proteins

Share to Remission Induction

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 18953436
DOI: 10.1593/neo.08778
PMCID: PMC2570603

Genes

MYCN
CPM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.PMID 18953436Read ↗

DNA‐damaging drug‐induced apoptosis sensitized by <i>N‐myc</i> in neuroblastoma cellsSemantic proximity Read ↗

Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.Semantic proximity Read ↗

Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH‐MYCN neuroblastoma mouse modelSemantic proximity Read ↗

In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and MetastasisSemantic proximity Read ↗

Mdm2 Deficiency Suppresses MYCN-Driven Neuroblastoma Tumorigenesis In VivoSemantic proximity Read ↗

p53 determines multidrug sensitivity of childhood neuroblastoma.Semantic proximity Read ↗

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.Semantic proximity Read ↗

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy CombinationSemantic proximity Read ↗

Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosisSemantic proximity Read ↗

Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.Semantic proximity Read ↗

The Novel Bcl-2 Inhibitor ABT-737 Is More Effective in Hypoxia and Is Able to Reverse Hypoxia-Induced Drug Resistance in Neuroblastoma CellsSemantic proximity Read ↗

Small-Molecule MDM2 Antagonists as a New Therapy Concept for NeuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.